Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

Endpoint Primary Endpoint Major Adverse Cardiovascular Events (MACE) 1. Death from cardiovascular cause 2. Non fatal myocardial infarction 3. Unstable angina g ppectoris 4. Heart failure requiring 5. Stroke hospitalization 6. Other cardiovascular events Secondary Endpoints - Revascularization - New-onset diabetes mellitus
Flow Flow Diagram Diagram for the Trial Trial June 2001 | April 2004 median Follow-upp 4.2 years June 30 2007 Randomized (n=2049) <strong>Candesartan</strong> -based therapy Standard therapy (n=1024) (n=1025) lost to follow-up 3 (0.3%) lost to follow-up 5 (0.5%) Statistical consideration ・Sample size <strong>of</strong> 2,049 with an 80% power to detect a 20% risk reduction at two-tailed 5%. ・Stratified, St tifi d permuted-block t d bl k randomization. d i ti ・The intention-to-treat approach.
Page 1 and 2: Comparison of Candesartan vs Amlodi
Page 3 and 4: 30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6: LIFE Incidence of Diabetes Mellitus
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55: Medications at at Randomization Ran
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 58 and 59: Candesartan vs vs Standard Standard
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 62 and 63: Summary IIn comparison i with i h s
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70: Predictors of new-onset atrial fibr

Comparison of Candesartan vs Amlodipine Comparison of ...

Create successful ePaper yourself

Delete template?

Save as template?